[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338937-105":59,"doc-detail-338937-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","breast-density-reduction-as-a-predictor-for-prognosis-in-premenopausal-women-with-estrogen-receptor-positive-breast-cancer-an-exploratory-analysis-of-the-updated-astrra-study","Breast density reduction as a predictor for prognosis in premenopausal women with estrogen receptor-positive breast cancer - an exploratory analysis of the updated ASTRRA study","","Retrospective cohort analysis examines whether mammographic breast density reduction (MDR) predicts prognosis in premenopausal patients with estrogen receptor-positive breast cancer, focusing on outcomes after adding ovarian function suppression (OFS). Using the updated ASTRRA trial results, baseline mammography and annual follow-up imaging up to 5 years were categorized by BI-RADS. MDR-positivity defined a downgrade within 2 years post-randomization. MDR-positivity related to improved disease-free survival only in the tamoxifen-plus-OFS group.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/breast-density-reduction-as-a-predictor-for-prognosis-in-premenopausal-women-with-estrogen-receptor-positive-breast-cancer-an-exploratory-analysis-of-the-updated-astrra-study/338937/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/breast-density-reduction-as-a-predictor-for-prognosis-in-premenopausal-women-with-estrogen-receptor-positive-breast-cancer-an-exploratory-analysis-of-the-updated-astrra-study/338937.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What study question investigates breast density reduction in premenopausal patients?","Question",{"text":113,"@type":114},"Whether mammographic breast density reduction (MDR) predicts prognosis, particularly when ovarian function suppression (OFS) is added to endocrine therapy.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was MDR-positivity defined in the ASTRRA updated analysis?",{"text":118,"@type":114},"MDR-positivity was defined as a downgrade in mammographic density (MD) grade on follow-up mammography within 2 years after randomization, using the pretreatment MD grade as the reference.",{"name":120,"@type":111,"acceptedAnswer":121},"Did MDR-positivity improve outcomes for both treatment groups?",{"text":122,"@type":114},"MDR-positivity was independently associated with favorable disease-free survival outcomes only in the tamoxifen-plus-OFS group, not in the tamoxifen-only group.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},338937,1790182276,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","’Retrospective Cohort Study  \nBreast density reduction as a predictor for prognosis in premenopausal women with estrogen receptor-positive breast cancer: an exploratory analysis of the updated ASTRRA study  \nSoong June Bae, MDa,b , Hee Jeong Kim, MD, PhDc , Hyun-Ah Kim, MD, PhDd , Jai Min Ryu, MD, PhDe , Seho Park, MD, PhDf, Eun-Gyeong Lee, MD, MScs , Seock-Ah Im, MD, PhDh , Yongsik Jung, MD, MScr , Min Ho Park, MD, PhDq , Kyong Hwa Park, MD, PhDk , Su Hwan Kang, MD, PhDo , Eunhwa Park, MD, PhDm , Sung Yong Kim, MD, PhDn , Min Hyuk Lee, MD, PhDl , Lee Su Kim, MD, PhDp , Anbok Lee, MD, PhDp , Woo Chul Noh, MD, PhDj , Sungchan Gwark, MD, PhDi , Seonok Kim, MScg , Joon Jeong, MD, PhDa,b,*  \nBackground: While the relationship between mammographic breast density reduction (MDR) and endocrine therapy efﬁcacy has been reported in estrogen receptor (ER)-positive breast cancer, it is still unclear in premenopausal women, especially in the case of adding ovarian function suppression (OFS) to antihormone therapy. The authors investigated the impact of MDR on prognosis stratiﬁed by treatment based on the updated results of the ASTRRA trial.  \nMaterials and methods: The ASTRRA trial, a randomized phase III study, showed that adding OFS to tamoxifen (TAM) improved survival in premenopausal women with estrogen receptor-positive breast cancer after chemotherapy. The authors updated survival outcomes and assessed mammography before treatment and the annual follow-up mammography for up to 5 years after treatment initiation. Mammographic density (MD) was classiﬁed into four categories based on the Breast Imaging-Reporting and Data System. MDR-positivity was deﬁned as a downgrade in MD grade on follow-up mammography up to 2 years after randomization, with pretreatment MD grade as a reference.  \nResults: The authors evaluated MDR in 944 of the 1282 patients from the trial, and 813 (86 .2%) had grade III or IV MD. There was no difference in the MDR-positivity rate between the two treatment groups [TAM-only group (106/476 (22.3%)) vs. TAM+OFS group (89/468 (19 .0%)); P = 0.217) . MDR-positivity was signiﬁcantly associated with better disease-free survival (DFS) in the TAM+OFS group (estimated 8-year DFS: 93 . 1% in MDR-positive vs. 82.0% in MDR-negative patients; HR: 0 .37; 95% CI: 0 .16–0.85; P = 0.019), but not in the TAM-only group (Pinteraction = 0.039) . MDR-positive patients who received TAM+OFS had a favorable DFS compared to MDR-negative patients who received only TAM (HR: 0 .30; 95% CI: 0 .13–0.70; P = 0.005) .  \nConclusion: Although the proportion of MDR-positive patients was comparable between both treatment groups, MDR-positivity was independently associated with favorable outcomes only in the TAM+OFS group.  \nKeywords: breast neoplasm, density, endocrine therapy, estrogen receptor-positive, ovarian function suppression  \naDepartment of Surgery, Gangnam Severance Hospital, bInstitute for Breast Cancer Precision Medicine, Yonsei University College of Medicine, cDivision of Breast, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, dDepartment of Surgery, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, eDivision of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, fDivision of Breast Surgery, Department of Surgery, Yonsei Cancer Center, Yonsei University College of Medicine, gDepartment of Clinical Epidemiology and Biostatistics, Asan Medical Center, hSeoul National University Hospital, Cancer Research Institute, Seoul National University, College of Medicine, iDepartment of Surgery, Ewha Womans University College of Medicine, Ewha Womans University Mokdong Hospital, jDepartment of Surgery, Konkuk Universitiy Medical Center, kKorea University Anam Hospital, Department of internal medicine, Division of Medical Oncology/Hematology, lDepartment of Surgery, Soonchunhyang University Hospital, Seoul, mDepartment of Surge","cbCaigx6ZTGvm4c8","https://ap.wps.com/l/cbCaigx6ZTGvm4c8","pdf",768419,"English","# Background\n# Materials and methods\n# Results\n# Conclusion\n# Keywords","[{\"question\":\"What study question investigates breast density reduction in premenopausal patients?\",\"answer\":\"Whether mammographic breast density reduction (MDR) predicts prognosis, particularly when ovarian function suppression (OFS) is added to endocrine therapy.\"},{\"question\":\"How was MDR-positivity defined in the ASTRRA updated analysis?\",\"answer\":\"MDR-positivity was defined as a downgrade in mammographic density (MD) grade on follow-up mammography within 2 years after randomization, using the pretreatment MD grade as the reference.\"},{\"question\":\"Did MDR-positivity improve outcomes for both treatment groups?\",\"answer\":\"MDR-positivity was independently associated with favorable disease-free survival outcomes only in the tamoxifen-plus-OFS group, not in the tamoxifen-only group.\"}]","Breast density reduction as a predictor for prognosis in premenopausal women with estrogen receptor-positive breast cancer - an exploratory analysis of the updated ASTRRA study | PDF",1790026639,23,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/14bee395eaf40e3dfdb49840db97065c.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/318c33330686e4eabe71250e14856c43.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/381537b7bf2758a713a1ad6d19de7005.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/943c690b214a30a7ea303ff78943e4a5.webp",980,1306]